Combined synopsis and solicitation
FY26 Pediatric FLU
75D30125R73357
Centers for Disease Control and Prevention, CDC Office of Acquisition Services. Pharmaceutical Preparation Manufacturing.
Awarded
Astrazeneca Pharmaceuticals LP
$122,760.00 obligated so far on USAspending
Description
As published on SAM.gov.
The Centers for Disease Control and Prevention (CDC) awards contracts to the manufacturers of pediatric vaccines for the purchase of standard commercial pediatric vaccines. Vaccines are one of the most cost-effective ways to prevent disease and reduce healthcare costs.
The Vaccine for Children (VFC) program established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993 (OBRA ’93), guarantees federal support for the purchase and supply of sufficient quantities of vaccine to the States to cover a defined group of children. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
Children (18 years-of-age or younger) who qualify for immunization through the VFC purchase program include those who are (1) Medicaid-eligible, (2) without health insurance, (3) American Indian/Alaska native (as defined in Subsection (h)(3) of the OBRA ’93), or (4) children with health insurance, which does not cover the cost of vaccines, if they receive their immunizations at a Federally-qualified health center or rural health clinic (as defined by the Social Security Act).
Health care providers who agree to certain requirements are eligible through the States to receive free vaccine through this VFC purchase program. The establishment of these contracts provides an opportunity to utilize VFC funds and Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial marketplace.
In addition, awardees may opt to purchase additional quantities of vaccine under any resulting contract to provide immunizations for children who are not federally vaccine-eligible children using state and local funds. Offerors for this requirement must be manufacturers of pediatric vaccines in accordance with 42 U.S.C. § 1396s.
The term "manufacturer" means any corporation, organization, or institution, whether public or private (including Federal, State, and local departments, agencies, and instrumentalities), which manufactures, imports, processes, or distributes under its label any pediatric vaccine. The term "manufacture" means to manufacture, import, process, or distribute a vaccine
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- Recipient
- Astrazeneca Pharmaceuticals LP
- UEI
- E5K2ZJ8CTJH4
- CAGE
- 36WK2
- Vendor location
- Wilmington, DE
- Contract
- 75D30126D20713
- Obligated
- $122,760.00, potential $9,300,000
- Actions
- 4 between December 29, 2025 and June 9, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Adult Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Glaxosmithkline, LLC
- UEI
- FRHTPHMZMX47
- CAGE
- 667E9
- Vendor location
- Durham, NC
- Contract
- 75D30126D20714
- Obligated
- $4,999,740.48, potential $13,916,000
- Actions
- 4 between December 29, 2025 and July 21, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Adult Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Sanofi Vaccines US Inc.
- UEI
- NCXBGGQ8YTU9
- CAGE
- 7V915
- Vendor location
- Swiftwater, PA
- Contract
- 75D30126D20717
- Obligated
- $2,000,377.66, potential $18,069,140
- Actions
- 3 between December 29, 2025 and June 9, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Adult Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Seqirus USA Inc.
- UEI
- N6U7P2B9VHS5
- CAGE
- 530P3
- Vendor location
- Summit, NJ
- Contract
- 75D30126D20720
- Obligated
- $1,004,522.04, potential $82,667,000
- Actions
- 4 between December 29, 2025 and June 9, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Adult Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Astrazeneca Pharmaceuticals LP
- UEI
- E5K2ZJ8CTJH4
- CAGE
- 36WK2
- Vendor location
- Wilmington, DE
- Contract
- 75D30126D20723
- Obligated
- $9,746,831.60, potential $32,010,000
- Actions
- 4 between December 29, 2025 and June 9, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Pediatric Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Glaxosmithkline, LLC
- UEI
- FRHTPHMZMX47
- CAGE
- 667E9
- Vendor location
- Durham, NC
- Contract
- 75D30126D20724
- Obligated
- $81,300,000.96, potential $167,376,000
- Actions
- 5 between December 29, 2025 and July 21, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Pediatric Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Sanofi Vaccines US Inc.
- UEI
- NCXBGGQ8YTU9
- CAGE
- 7V915
- Vendor location
- Swiftwater, PA
- Contract
- 75D30126D20725
- Obligated
- $68,661,449.49, potential $337,558,625
- Actions
- 4 between December 29, 2025 and June 9, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Pediatric Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
- Recipient
- Seqirus USA Inc.
- UEI
- N6U7P2B9VHS5
- CAGE
- 530P3
- Vendor location
- Summit, NJ
- Contract
- 75D30126D20726
- Obligated
- $57,772,604.95, potential $168,112,600
- Actions
- 4 between December 29, 2025 and June 9, 2026
- Competition
- Full and Open Competition, 4 offers received
- Set-aside reported
- No Set Aside Used.
- Described as
- Pediatric Flu Vaccines
- Match
- solicitation number 75D30125R73357 equals the FPDS solicitation identifier; same awarding office 75D301 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
August 14, 2025
Combined synopsis and solicitation
Due August 28, 2025 at 1:00 PM EDT. SAM.gov, notice e62f4dc5ffda4a6995908b7c831faa69
August 19, 2025
Combined synopsis and solicitation
Due August 28, 2025 at 1:00 PM EDT. SAM.gov, notice 2d957bd88a9840a7961edda96d317295
August 19, 2025
Combined synopsis and solicitation
Due August 28, 2025 at 1:00 PM EDT. SAM.gov, notice 6373eef4cfad4de0acaed645596b2b50
Points of contact
- James Spriglerzbs6@cdc.gov
- Chad Turnerukr9@cdc.gov
Also open from this buyer
- (Presolicitation Notice) Intent to Sole Source - Grants Management TrainingPresolicitationNAICS 611430GeorgiaPR00251Closes tomorrowSep 17
- (Presolicitation Notice) Intent to Sole Source - Biol Specimens for Lenacapavir PEPPresolicitationNAICS 621511GeorgiaPR97866Closes tomorrowSep 17
- Facilitating Research, Programmatic, and Operational Support of the National Amyotrophic Lateral Sclerosis’ (ALS) Biorepository in support of the ALS Registry ActCombined synopsis and solicitationSmall businessNAICS 621991Georgia75D301-Q-26-95343Closes tomorrowSep 17
- The National ALS Registry Expansion of Outreach and Awareness to Persons with ALS in Select States Covered by the Amyotrophic Lateral Sclerosis (ALS) AssociationPresolicitationNAICS 813212Georgia2026-ALSACloses tomorrowSep 17
- Installation, Configuration, Software Upgrade, Preventive Maintenance, and Repair Services for the Government-Owned Sci-Print VXL/VXQ Automated Tube Labeling SystemSolicitationNAICS 334516Georgia75D30126Q79281Closes tomorrowSep 17